Boehringer Ingelheim Pharmaceuticals Inc., of Ridgefield, Conn., part of Boehringer Ingelheim GmbH, reported data from two Phase III trials involving two investigational oncology compounds – afatinib and nintedanib – in two distinct patient populations with advanced non-small-cell lung cancer (NSCLC

The third compound due for Phase III testing in the second half of this year is selumetinib, a MEK inhibitor used in combination with docetaxel as a second-line therapy for patients with KRAS mutation-positive and metastatic non-small-cell lung cancer

The FDA approved Tarceva (erlotinib) tablets for first-line treatment of metastatic non-small-cell lung cancer characterized by tumors with epidermal growth factor receptor-activating mutations

The trial (PINNACLE) will evaluate OMP-59R5 in combination with cisplatin and etoposide in first-line, extensive-stage small-cell lung cancer

The highest response was observed in non-small-cell lung cancer and melanoma, but tumor shrinkage also was observed in kidney cancer, colorectal cancer and gastric cancer

We've also amended the Phase I trial to look at small subsets of patients with non-small-cell lung cancer, renal cancer and hepatocellular cancer," because FANG brought cause for hope in those tumors, too.

Complete and partial radiological remissions were observed in patients with small-cell lung, bladder, breast, endometrial and ovarian cancers, neuroendocrine tumors and synovial sarcoma...The company is planning a potential pivotal trial in small-cell lung cancer and a confirmatory activity trial in endometrial cancer

The blockbuster drug was approved by the FDA in 2004 in locally advanced or metastatic non-small-cell lung cancer (NSCLC) after failure of at least one prior chemotherapy regimen

In their studies, which they published in the May 13, 2013, issue of Cancer Cell, the team sequenced the ErbB3 genes of more than 500 tumors, mainly of colorectal, gastric and non-small-cell lung cancers

cell lung cancer Clinical data suggest it has the potential to overcome drug-resistance mutations 4/12/13 ArQule Inc. (Woburn, Mass.) ARQ 092 AKT inhibitor Advanced or metastatic solid tumors Phase I data showed it inhibits the AKT pathway and has a manageable safety profile 4/10/13 BIND Therapeutics Inc. (Cambridge, Mass.) BIND-014 Lead Accurin candidate Advanced or metastatic solid tumors Phase I data showed it was generally safe and well tolerated at the maximum tolerated dose of 60 mg/m2 and

Phase IIa data showed evidence of efficacy, with five patients reported as being in remission at the final (six-month) follow-up 4/23/13 CANCER Axelar AB (Stockholm, Sweden) AXL1717 Small-molecule IGF-1 receptor inhibitor Non-small-cell lung cancer Phase II data showed it is effective 4/3/13 BioInvent International AB (Lund, Sweden) BI-505 A human antibody that binds to the ICAM-1 adhesion protein Smoldering multiple myeloma The first patient has been treated in a Phase II study 4/23/13

In the space of a few weeks that year the FDA approved Pfizer Inc.'s targeted therapy Xalkori (crizotinib) to treat certain patients with late-stage, non-small cell lung cancers (NSCLC) who express the abnormal anaplastic lymphoma kinase (ALK) gene...Marketing authorization application (MAA) filings for both vintafolide and etarfolatide have been accepted for review by the European Medicines Agency (EMA), and they are are currently being evaluated in a Phase III randomized, double-blind trial for

a separate Phase III trial reached an enrollment target of 350 patients, plus an additional 41 who were permitted to participate 4/12/13 Sirtex Medical Ltd. (Woburn, Mass.) SIR-Spheres Microspheres Metastatic colorectal cancer Completed patient recruitment with more than 500 patients enrolled in the landmark SIRFLOX trial 4/16/13 Synta Pharmaceuticals Corp. (Lexington, Mass.) Ganetespib Hsp90 inhibitor Non-small-cell lung adenocarcinoma The first patients have been treated in the confirmatory

CytRx Corp., of Los Angeles, said an independent data safety monitoring committee (DSMC) recommended the company discontinue its Phase IIb trial with tamibarotene as first-line treatment in advanced non-small-cell lung cancer

Endocyte Inc., of West Lafayette, Ind., landed its deal with Merck in April 2012, receiving $120 million up front, with the potential for $880 million in milestone payments on development, regulatory and commercial goals for EC145 in six cancer indications. (See BioWorld Today, April 17, 2012.) EC145 is designed to preferentially target the chemotherapy agent to fast-growing cancer cells that actively take up folate via the folate receptor, which is expressed in ovarian, non-small-cell lung

With the multiple Phase III trials ahead, which include work by partner AstraZeneca plc, of London, with selumetinib in non-small-cell lung cancer (NSCLC), "progress in partnered programs will likely drive valuation upside from current levels," Yun wrote

Endocyte Inc., of West Lafayette, Ind., landed its deal with Merck in April 2012, receiving $120 million up front, with the potential for $880 million in milestone payments on development, regulatory and commercial goals for EC145 in six cancer indications. (See BioWorld Today, April 17, 2012.) EC145 is designed to preferentially target the chemotherapy agent to fast-growing cancer cells that actively take up folate via the folate receptor, which is expressed in ovarian, non-small-cell lung

Merrimack Pharmaceuticals Inc., of Cambridge, Mass., reported that the last patient has been enrolled in the first cohort of a randomized Phase II trial of MM-121 in combination with erlotinib for the treatment of non-small-cell lung cancer (NSCLC

The company has had early success with its lead internal program, BIND-014, a prostate-specific membrane antigen-targeted docetaxel compound, in development for non-small-cell lung cancer, prostate cancer and bladder cancer